Jiangsu Recbio Technology Co., Ltd.
HKEX:2179.HK
8.4 (HKD) • At close November 5, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 8.81 | 8.81 | 12.89 | 12.89 | 2.299 | 2.299 | 1.679 | 1.679 | 0.984 | 0.984 | 2.789 | 0 | 0 | 0 | 1.319 |
| Cost of Revenue
| 4.525 | 4.525 | 4.019 | 4.019 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 4.285 | 4.285 | 8.871 | 8.871 | 2.299 | 2.299 | 1.679 | 1.679 | 0.984 | 0.984 | 2.789 | 0 | 0 | 0 | 1.319 |
| Gross Profit Ratio
| 0.486 | 0.486 | 0.688 | 0.688 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 |
| Reseach & Development Expenses
| 102.611 | 102.611 | 120.013 | 120.013 | 123.911 | 123.911 | 180.988 | 180.988 | 177.235 | 177.235 | 101.174 | 166.947 | 102.416 | 102.416 | 78.357 |
| General & Administrative Expenses
| 27.348 | 27.348 | 32.84 | 32.84 | 39.044 | 39.044 | 39.317 | 39.317 | 38.335 | 38.335 | 112.249 | -53.016 | 41.906 | 41.906 | 4.794 |
| Selling & Marketing Expenses
| 0.764 | 0.764 | 1.516 | 1.516 | 2.72 | 2.72 | 2.438 | 2.438 | 1.889 | 1.889 | 2.555 | 0.906 | 0 | 0 | 0 |
| SG&A
| 28.112 | 28.112 | 34.356 | 34.356 | 41.763 | 41.763 | 41.755 | 41.755 | 40.224 | 40.224 | 114.804 | -52.11 | 41.906 | 41.906 | 4.794 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -89.238 | 86.357 | 0 | 0 | 1.69 |
| Operating Expenses
| 130.723 | 130.723 | 154.369 | 162.927 | 150.472 | 150.472 | 198.172 | 198.172 | 182.71 | 182.71 | 126.74 | 201.194 | 139.05 | 139.05 | 84.841 |
| Operating Income
| -126.438 | -126.438 | -145.498 | -145.498 | -163.376 | -163.376 | -221.064 | -221.064 | -216.474 | -216.474 | -138.364 | -194.479 | -142.663 | -142.663 | -86.734 |
| Operating Income Ratio
| -14.352 | -14.352 | -11.288 | -11.288 | -71.079 | -71.079 | -131.703 | -131.703 | -219.994 | -219.994 | -49.611 | 0 | 0 | 0 | -65.757 |
| Total Other Income Expenses Net
| 1.62 | 1.62 | -2.254 | -2.254 | 24.905 | 24.905 | 31.624 | 31.624 | 37.916 | 37.916 | 1.162 | 4.417 | -22.488 | -22.488 | -20.172 |
| Income Before Tax
| -124.818 | -124.818 | -147.751 | -147.751 | -138.471 | -138.471 | -189.44 | -189.44 | -178.559 | -178.559 | -137.202 | -190.062 | -165.151 | -165.151 | -106.906 |
| Income Before Tax Ratio
| -14.168 | -14.168 | -11.462 | -11.462 | -60.244 | -60.244 | -112.862 | -112.862 | -181.462 | -181.462 | -49.194 | 0 | 0 | 0 | -81.051 |
| Income Tax Expense
| -0.251 | -0.251 | 1.953 | 1.953 | -2.196 | -2.196 | -2.931 | -2.931 | -3.716 | -3.716 | -1.167 | -4.417 | 0 | 0 | 20.172 |
| Net Income
| -124.568 | -124.568 | -149.704 | -149.704 | -136.275 | -136.275 | -186.509 | -186.509 | -174.843 | -174.843 | -136.035 | -185.645 | -165.151 | -165.151 | -127.078 |
| Net Income Ratio
| -14.139 | -14.139 | -11.614 | -11.614 | -59.288 | -59.288 | -111.116 | -111.116 | -177.686 | -177.686 | -48.776 | 0 | 0 | 0 | -96.344 |
| EPS
| -0.26 | -0.26 | -0.31 | -0.31 | -0.28 | -0.28 | -0.39 | -0.39 | -0.38 | -0.38 | -0.3 | -0.41 | -0.42 | -0.42 | -0.27 |
| EPS Diluted
| -0.26 | -0.26 | -0.31 | -0.31 | -0.28 | -0.28 | -0.39 | -0.39 | -0.38 | -0.38 | -0.3 | -0.41 | -0.42 | -0.42 | -0.27 |
| EBITDA
| -108.833 | -108.833 | -132.297 | -132.297 | -152.638 | -152.638 | -213.823 | -213.823 | -210.011 | -210.011 | -131.921 | -188.535 | -139.565 | -139.565 | -81.918 |
| EBITDA Ratio
| -12.353 | -12.353 | -10.264 | -10.264 | -66.407 | -66.407 | -127.389 | -127.389 | -213.426 | -213.426 | -47.3 | 0 | 0 | 0 | -62.106 |